Document is current
Any future updates will be listed below
-
Authors
Nacev, Benjamin A. https://orcid.org/0000-0003-4991-2492
Sanchez-Vega, Francisco https://orcid.org/0000-0002-2990-4893
Smith, Shaleigh A. https://orcid.org/0000-0003-4597-9876
Antonescu, Cristina R. https://orcid.org/0000-0002-9717-8205
Rosenbaum, Evan
Shi, Hongyu
Tang, Cerise
Socci, Nicholas D.
Rana, Satshil
Gularte-Mérida, Rodrigo https://orcid.org/0000-0002-4383-2523
Zehir, Ahmet https://orcid.org/0000-0001-5406-4104
Gounder, Mrinal M.
Bowler, Timothy G.
Luthra, Anisha
Jadeja, Bhumika https://orcid.org/0000-0002-3580-8240
Okada, Azusa
Strong, Jonathan A.
Stoller, Jake
Chan, Jason E. https://orcid.org/0000-0003-0552-8544
Chi, Ping
D’Angelo, Sandra P. https://orcid.org/0000-0002-3736-3783
Dickson, Mark A.
Kelly, Ciara M. https://orcid.org/0000-0002-4393-8088
Keohan, Mary Louise
Movva, Sujana
Thornton, Katherine
Meyers, Paul A.
Wexler, Leonard H. https://orcid.org/0000-0003-0724-8263
Slotkin, Emily K.
Glade Bender, Julia L. https://orcid.org/0000-0001-5316-6440
Shukla, Neerav N.
Hensley, Martee L.
Healey, John H. https://orcid.org/0000-0002-0802-1186
La Quaglia, Michael P.
Alektiar, Kaled M.
Crago, Aimee M.
Yoon, Sam S.
Untch, Brian R.
Chiang, Sarah
Agaram, Narasimhan P.
Hameed, Meera R.
Berger, Michael F. https://orcid.org/0000-0003-3882-5000
Solit, David B. https://orcid.org/0000-0002-6614-802X
Schultz, Nikolaus https://orcid.org/0000-0002-0131-4904
Ladanyi, Marc
Singer, Samuel
Tap, William D.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P50 CA217694, P30 CA008748)
U.S. Department of Health & Human Services | National Institutes of Health
- License Information
-
More Information
Article History
Received: 18 October 2021
Accepted: 2 May 2022
First Online: 15 June 2022
Competing interests
: M.M.G. has served on advisory boards for Athenex, Ayala, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Epizyme, Karyopharm, Rain, SpringWorks Therapeutics, Tracon, and TYME Technologies; provides consulting services through Guidepoint, GLG Pharma, Third Bridge, and Flatiron Health; has received speaking honoraria from Medscape, More Health, Physicians Education Resource and touchIME; receives publishing royalties from Wolters Kluwer; holds a patent for a patient-reported outcome tool licensed through the institution; and has performed research without compensation in collaboration with Foundation Medicine. T.G.B. is currently employed by Pfizer. P.C. has served on advisory boards or consulted for Deciphera, Exelixis, NingboNewBay Medical Technology, Novartis, and Zai Lab, and has received institutional research funding from Deciphera, Ningbo NewBay Medical Technology, Novartis, and Pfizer/Array. S.P.D. has received institutional research funding from Amgen, Bristol Meyers Squibb, Deciphera, EMD Serono, Incyte, Merck, and Nektar Therapeutics, has served as a consultant or on advisory boards for Adaptimmune, Amgen, EMD Serono, GlaxoSmithKline, Immune Design, Immunocore, Incyte, Merck, and Nektar Therapeutics, Pfizer, Servier, and Rain Therapeutics, and has served on data safety monitoring boards for Adaptimmune, GlaxoSmithKline, Merck, and Nektar Therapeutics. M.A.D. has received institutional research funding from Aadi Bioscience and Eli Lilly. C.M.K. has received research funding from Amgen, Exicure, Incyte, Kartos, Merck, Servier, and Xencor; consulted for Chemocentryx and Kartos; served on a data safety review board for Kartos; and served on advisory boards for Immunicum. S.M. has received research funding from Ascentage Pharma and Hutchison Medi Pharma. K.T. has served as a consultant for Epizyme and GlaxoSmithKline. P.A.M. has served on advisory boards or consulted for Margaux Miracle Foundation, Salarius Pharmaceuticals, and Takeda, and has an immediate family member who has served on advisory boards or consulted for Boehringer Ingelheim and Genentech and received honoraria from Eastern Pulmonary Conference. E.K.S. has consulted for Epizyme. J.L.G.B. has received institutional research support from Amgen, Bayer, Bristol Myers Squibb, Celgene, Cellectar Biosciences, Eisai, Ignyta, Lilly, Loxo Oncology, Merck, Novartis, and Roche; and served on data safety monitoring boards for Abbvie, Merck, and SpringWorks and on an advisory board for Bristol Myers Squibb. M.L.H. has served on advisory boards and consulted for Eli Lilly, GlaxoSmithKline, and Thrive Bioscience, received author royalties from UpToDate, and received speaker honoraria from Research to Practice; her spouse is employed by Sanofi. J.H.H. has consulted for Daiichi Sankyo and Stryker and is a trustee of the Musculoskeletal Transplant Foundation and board member for the Make It Better Foundation to Cure Childhood Osteosarcoma. A.M.C. has served on an advisory board for SpringWorks. B.R.U. is co-inventor of intellectual property (H.R.A.S. as a biomarker of tipifarnib efficacy) that has been licensed by MSK to Kura Oncology. S.C. has consulted for AstraZeneca. M.F.B. has served as a consultant for Eli Lilly and PetDx. W.D.T. has consulted for Adcendo, Amgen, AmMax Bio, Ayala Pharmaceuticals, Bayer, Blueprint, C4 Therapeutics, Cogent, Daiichi Sankyo, Deciphera, Eli Lilly, EMD Serono, Epizyme, Foghorn Therapeutics, Kowa, Medpacto, Mundipharma, and Servier; served on advisory boards for Certis Oncology and Innova Therapeutics; holds two patents for biomarkers of CDK4 inhibitor efficacy in cancer, and is a co-founder of and owns stock in Atropos Therapeutics. D.B.S. has consulted for BridgeBio, FORE Therapeutics, Loxo/Lilly Oncology, Pfizer, Scorpion Therapeutics, and Vividion Therapeutics. All other authors have no competing relationships to disclose.
